LB Pharmaceuticals tops 2025 biotech IPO list with $285m Nasdaq debut
US-based biotech LB Pharmaceuticals has broken the 2025 biotech initial public offering (IPO) drought – and with style – raising …
Post
-
-
Podcast: key trials and trends from ESC Congress 2025
Eyes in the pharma and medtech industries are directed to the European Society of Cardiology (ESC) Congress every year to …
-
AbbVie extends Rinvoq exclusivity by four years after generics settlements
AbbVie has bolstered the sales outlook of its blockbuster autoimmune drug Rinvoq (upadacitinib) by extending its exclusivity until 2037. The company …
-
Kashiv signs deal with CRISTÁLIA for Xolair biosimilar in LATAM
Kashiv BioSciences has entered a partnership with Brazilian biopharmaceutical firm CRISTÁLIA to facilitate the marketing of ADL-018/Omalizumab, a proposed biosimilar …
-
GTCR to acquire generic drug maker Zentiva
Czech producer of generic medications Zentiva is poised for a change in ownership as Advent has agreed to sell the …
-
MSD calls off £1bn UK expansion amid government-big pharma tensions
Merck & Co (MSD) has ditched plans for its £1bn R&D centre in London, UK, while ceasing drug discovery and …
-
UK pharma industry risks losing world-leading status as investment plummets
The UK is at risk of losing its world-leading life sciences status due to investment being captured elsewhere on the …
-
Kriya gains $320m in Series D for gene therapy development
Kriya Therapeutics has closed an oversubscribed Series D funding round, raising $320m, aimed at propelling its gene therapy pipeline targeting …
-
Sanofi’s Tzield gains approval in China for T1D management
China’s National Medical Products Administration (NMPA) has approved Sanofi’s Tzield (teplizumab), making it the first disease-modifying therapy for autoimmune type …
-
Top 20 biopharma market caps fall 5.7% amid industry challenges
The biopharmaceutical industry faces headwinds from the Trump administration’s ongoing tariffs and drug pricing pressures in the US. As a …
-
Trump tasks FDA to crack down on misleading drug advertising
US President Donald Trump is launching an enforcement drive against pharmaceutical companies and social media influencers who are responsible for …
-
Capricor refutes FDA’s DMD deramiocel rejection in public statement
Capricor Therapeutics has publicised a statement addressing the US Food and Drug Administration’s (FDA) decision to reject its Duchenne muscular …
-
Novo Nordisk slashes 11% of workforce as Eli Lilly pressure tightens
Novo Nordisk will cut 9,000 jobs as part of a savings plan as the drugmaker fails to grapple with the …
-
Kytopen and BlueWhale Bio partner for cell therapy innovation
Kytopen, a provider of continuous flow cellular engineering technologies, has collaborated with BlueWhale Bio to advance the manufacturing process of …
-
Health Canada approves Medison and Ipsen’s Bylvay to treat ALGS
Health Canada has approved Medison Pharma and Ipsen’s Bylvay (odevixibat) to treat cholestatic pruritus in patients aged 12 months and …
